P/B
4,4
MediciNova
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.
$163.4M
Market Cap • 9/18/2026
2000
(26 years)
Founded
2006
(20 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
177,5
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
0,8
EPS
—
Market Cap
Market Cap
163,4M
EV
138,1M
EV/Revenue
150
EV/EBITDA
-11,7
EV/EBIT
-11,7
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
0%
Total Yield
0%
Payout
0%
Retained Earnings
-443,6M
Profitability
Gross Margin
37,7%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
588,6%
Capex/Revenue
1,5%
Capex/D&A
71,7%
Capex/OCF
-0,2%
SBC/OCF
—
% PPE
0,3%
% Goodwill
23,7%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
-25,5%
CAGR Op. Income 5Y
1%
CAGR Net Income 5Y
-0,7%
CAGR EPS 5Y
-1,8%
CAGR OCF 5Y
1,2%
Leverage
N.D./EBITDA
2,1
Debt/Equity
0%
Current Ratio
8,8
Quick Ratio
8,6
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!